Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome

JAAD Case Rep. 2022 Mar 17:29:106-109. doi: 10.1016/j.jdcr.2022.03.017. eCollection 2022 Nov.

¹ Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
² Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
³ Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
⁴ Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
⁵ Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
⁶ Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing, People's Republic of China.

No abstract available

Keywords: HES, hypereosinophilic syndrome; IL, interleukin; eosinophils; pulmonary; skin; therapy; type 2 inflammation.

Publication types